El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

720617.pdf (736.44 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-08

Llicència de publicació

cc-by (c) Grillo, Sara et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/198352

Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: study protocol for the SAFO trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1136/bmjopen-2021-051208

Resum

Introduction: Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia is a frequent condition, with high mortality rates. There is a growing interest in identifying new therapeutic regimens able to reduce therapeutic failure and mortality observed with the standard of care of beta-lactam monotherapy. In vitro and small-scale studies have found synergy between cloxacillin and fosfomycin against S. aureus. Our aim is to test the hypothesis that cloxacillin plus fosfomycin achieves higher treatment success than cloxacillin alone in patients with MSSA bacteraemia. Methods: We will perform a superiority, randomised, open-label, phase IV-III, two-armed parallel group (1:1) clinical trial at 20 Spanish tertiary hospitals. Adults (≥18 years) with isolation of MSSA from at least one blood culture ≤72 hours before inclusion with evidence of infection, will be randomly allocated to receive either cloxacillin 2 g/4-hour intravenous plus fosfomycin 3 g/6-hour intravenous or cloxacillin 2 g/4-hour intravenous alone for 7 days. After the first week, sequential treatment and total duration of antibiotic therapy will be determined according to clinical criteria by the attending physician. Primary endpoints: (1) Treatment success at day 7, a composite endpoint comprising all the following criteria: patient alive, stable or with improved quick-Sequential Organ Failure Assessment score, afebrile and with negative blood cultures for MSSA at day 7. (2) Treatment success at test of cure (TOC) visit: patient alive and no isolation of MSSA in blood culture or at another sterile site from day 8 until TOC (12 weeks after randomisation). We assume a rate of treatment success of 74% in the cloxacillin group. Accepting alpha risk of 0.05 and beta risk of 0.2 in a two-sided test, 183 subjects will be required in each of the control and experimental groups to obtain statistically significant difference of 12% (considered clinically significant). Ethics and dissemination: Ethical approval has been obtained from the Ethics Committee of Bellvitge University Hospital (AC069/18) and from the Spanish Medicines and Healthcare Product Regulatory Agency (AEMPS, AC069/18), and is valid for all participating centres under existing Spanish legislation. The results will be presented at international meetings and will be made available to patients and funders.

Matèries

Malalties infeccioses, Microbiologia, Assaigs clínics

Matèries (anglès)

Communicable diseases, Microbiology, Clinical trials

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Medicina)

Citació

GRILLO, Sara, CUERVO REQUENA, Guillermo, CARRATALÀ, Jordi, SANJUAN, Rafael, AGUADO, José maría, MORATA, Laura, GÓMEZ-ZORRILLA MARTÍN, Silvia, LÓPEZ-CONTRERAS, Joaquín, GASCH, Oriol, GOMILA GRANGE, Aina, IFTIMIE, Simona, GARCIA PARDO, Graciano, CALBO, Esther, BOIX PALOP, Lucía, ORIOL, Isabel, JOVER-SÁENZ, Alfredo, LÓPEZ-CORTÉS, Luis eduardo, EUBA, Gorane, AGUIRREGABIRIA, Malen, GARCIA-PAIS, Maria jose, GIOIA, Francesca, PAÑO PARDO, José ramón, PEDRO-BOTET MONTOYA, Ma luisa, BENÍTEZ, Rosa m., PÉREZ-RODRÍGUEZ, Maria teresa, MEIJE, Yolanda, LOECHES-YAGÜE, Maria belén, HORNA, Gertrudis, BERBEL, Dàmaris, DOMÍNGUEZ, María ángeles, PADULLÉS ZAMORA, Ariadna, COBO SACRISTÁN, Sara, HEREU, Pilar, VIDELA, Sebastià, TEBÉ, Cristian, PALLARÈS, Natàlia, MIRÓ MEDA, José m. (josé maría), PUJOL, Miquel, SAFO study group, Spanish Network for Research in Infectious Diseases (REIPI).. Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: study protocol for the SAFO trial. _BMJ Open_. 2021. Vol. 11, núm. 8, pàgs. e051208. [consulta: 3 de gener de 2026]. ISSN: 2044-6055. [Disponible a: https://hdl.handle.net/2445/198352]

Exportar metadades

JSON - METS

Compartir registre